TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Mobile Phone Based Medication Reminder Program for Patients in China With Coronary Heart Disease: A Pilot Study
Brief Summary: This study evaluates the feasibility and acceptability of using mobile applications to improve medication adherence. Participants in the experimental group will receive educational materials and daily reminders through mobile applications. While, participants in the control group will receive only educational materials. After the intervention, interviews will be conducted among participants through phone calls.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge plus AI Chat Bot; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Intervention Type: BEHAVIORAL; Name: Nudge; Assigned to Arm(s): Generic Nudge, Optimized nudge, Optimized nudge plus AI Chat Bot
B: Arm Label: Mobile App Group; Type: EXPERIMENTAL; Interventions: Other: Daily reminders of taking medications, Other: Educational materials | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational materials | Intervention Type: OTHER; Name: Daily reminders of taking medications; Assigned to Arm(s): Mobile App Group | Intervention Type: OTHER; Name: Educational materials; Assigned to Arm(s): Control Group, Mobile App Group
C: Arm Label: Intervention SMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervention SMS | Arm Label: Control SMS; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control SMS | Intervention Type: BEHAVIORAL; Name: Intervention SMS; Assigned to Arm(s): Intervention SMS | Intervention Type: BEHAVIORAL; Name: Control SMS; Assigned to Arm(s): Control SMS
D: Arm Label: Text Message Group; Type: EXPERIMENTAL; Interventions: Behavioral: Text Message, Other: Website | Arm Label: Application Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Application, Other: Website | Arm Label: Website-Control; Type: EXPERIMENTAL; Interventions: Other: Website | Intervention Type: BEHAVIORAL; Name: Text Message; Assigned to Arm(s): Text Message Group | Intervention Type: BEHAVIORAL; Name: Mobile Application; Assigned to Arm(s): Application Group | Intervention Type: OTHER; Name: Website; Assigned to Arm(s): Application Group, Text Message Group, Website-Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Investigate the Use of Trans-perineal Trigger Point Dry Needling With Manual Therapy and to Compare the Outcome With Manual Therapy Treatment for Chronic Pelvic Pain With Dyspareunia. A Randomized Clinical Trial.
Brief Summary: Chronic Pelvic Pain (CPP) are around 10% of gynaecology referrals.Non-relaxing pelvic floor dysfunction (NRPFD) is an under-appreciated cause for CPP with dyspareunia where no other pathology exists. The effectiveness of manual therapy in studies have shown statistically significant pre and post treatment differences.However no study has reviewed the efficacy of inclusion of trans- perineal trigger point dry needling used with manual therapy for NRPFD. This study will investigate the effectiveness of trans-perineal trigger point dry needling used with manual therapy techniques for CPP.


Options:
A: Arm Label: Life-Stress Interview; Type: EXPERIMENTAL; Interventions: Behavioral: Life-Stress Interview | Arm Label: Wait-list Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Life-Stress Interview; Assigned to Arm(s): Life-Stress Interview
B: Arm Label: Manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual therapy | Arm Label: Dry needling & manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual therapy, Procedure: Trigger point dry needling | Intervention Type: PROCEDURE; Name: Manual therapy; Assigned to Arm(s): Dry needling & manual therapy, Manual therapy | Intervention Type: PROCEDURE; Name: Trigger point dry needling; Assigned to Arm(s): Dry needling & manual therapy
C: Arm Label: Pelvic Floor Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pelvic Floor Physical Therapy | Arm Label: Bladder Instillations; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bladder Instillations | Intervention Type: PROCEDURE; Name: Pelvic Floor Physical Therapy; Assigned to Arm(s): Pelvic Floor Physical Therapy | Intervention Type: DRUG; Name: Bladder Instillations; Assigned to Arm(s): Bladder Instillations
D: Arm Label: Botulinum toxin A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A | Arm Label: Control arm-Normal saline instillation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline instillation | Intervention Type: DRUG; Name: Botulinum toxin A; Assigned to Arm(s): Botulinum toxin A | Intervention Type: DRUG; Name: Normal saline instillation; Assigned to Arm(s): Control arm-Normal saline instillation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Usefulness of Ultrasound Guided Technique Insertion of Radial Artery Catheter in Neonates and Infants
Brief Summary: The investigators are trying to compare the ultrasound-guided technique vs. palpation method for radial arterial cannulation in infants.


Options:
A: Arm Label: Palpation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radial arterial cannulation | Arm Label: Ultrasound group; Type: EXPERIMENTAL; Interventions: Procedure: Radial arterial cannulation | Intervention Type: PROCEDURE; Name: Radial arterial cannulation; Assigned to Arm(s): Palpation group, Ultrasound group
B: Arm Label: Palpation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Palpation | Arm Label: Ultrasound; Type: EXPERIMENTAL; Interventions: Procedure: Ultrasound guidance | Intervention Type: PROCEDURE; Name: Ultrasound guidance; Assigned to Arm(s): Ultrasound | Intervention Type: PROCEDURE; Name: Palpation; Assigned to Arm(s): Palpation
C: Arm Label: Conventional method (CM); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radial artery cannulation | Arm Label: Ultrasound guided method (USG); Type: EXPERIMENTAL; Interventions: Procedure: Radial artery cannulation | Intervention Type: PROCEDURE; Name: Radial artery cannulation; Assigned to Arm(s): Conventional method (CM), Ultrasound guided method (USG)
D: Arm Label: With ultrasound guidance; Type: EXPERIMENTAL; Interventions: Procedure: Artery puncture with ultrasound guidance | Arm Label: Without ultrasound guidance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Artery puncture without ultrasound guidance | Intervention Type: PROCEDURE; Name: Artery puncture with ultrasound guidance; Assigned to Arm(s): With ultrasound guidance | Intervention Type: PROCEDURE; Name: Artery puncture without ultrasound guidance; Assigned to Arm(s): Without ultrasound guidance

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Primary Care for Diabetes and Cardiovascular Disease in Less Developed Countries: Pragmatic Trial of the Practical Approach to Care Kit
Brief Summary: This study will evaluate a complex intervention based on a patient management tool (PMT), combined with educational outreach to primary care doctors, nurses and other health workers, in the Brazilian city of Florianopolis. The intervention is aimed at improving the quality of primary health care and health outcomes, in adults with diabetes and cardiovascular disease (CVD). The effectiveness of the intervention will be assessed by randomly allocating 48 primary care clinics to receive the intervention or not, and comparing patient and clinic level endpoints that reflect the health and quality of care provided over the following year. About 11000 patients known to have been diagnosed with diabetes mellitus and 32000 with CVD (defined as having a diagnosis of hypertension, ischemic heart disease, heart failure or cerebrovascular disease) in participating clinics will be included in the study. About 7800 of them have diagnoses of both CVD and stroke. The primary endpoints will be 1. Number of participants in whom at least one of the following tests was recorded: body mass index, plasma glucose, serum cholesterol, electrocardiogram, and 2. in participants with a diagnosis of hypertension recorded previously, average systolic blood pressure recorded. Secondary endpoints will include the individual components of the composite scores, health measures (hospital admissions and deaths), and indicators of appropriate diagnosis of comorbid conditions such as depression. Eligible patients will be identified and outcomes measured using electronic medical records.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Outreach education training | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: No outreach education training | Intervention Type: BEHAVIORAL; Name: Outreach education training; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: No outreach education training; Assigned to Arm(s): Control
B: Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Case Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management
C: Arm Label: Genie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GENIE - social networking tool | Arm Label: Normal Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: GENIE - social networking tool; Assigned to Arm(s): Genie
D: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: telerehabilitation | Arm Label: Standard chronic care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: telerehabilitation; Assigned to Arm(s): Telerehabilitation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors
Brief Summary: Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors


Options:
A: Arm Label: Provera; Type: EXPERIMENTAL; Interventions: Drug: Provera 10 mg. | Arm Label: Orgalutrán Ganirelix (GnRH antagonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ganirelix (GnRH antagonist) | Intervention Type: DRUG; Name: Provera 10 mg.; Assigned to Arm(s): Provera | Intervention Type: DRUG; Name: Ganirelix (GnRH antagonist); Assigned to Arm(s): Orgalutrán Ganirelix (GnRH antagonist)
B: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
C: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
D: Arm Label: Progevera; Type: EXPERIMENTAL; Interventions: Drug: Progevera | Arm Label: Orgalutran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Orgalutran | Intervention Type: DRUG; Name: Progevera; Assigned to Arm(s): Progevera | Intervention Type: DRUG; Name: Orgalutran; Assigned to Arm(s): Orgalutran

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Homebased Cardiac Rehabilitation Program of Mixed Surveillance Using NUUBO Monitoring Vest in Patients With Ischemic Heart Disease at Moderate Cardiovascular Risk
Brief Summary: The current state of mobile communication and technology is a tool to support home programs for chronic disease management, useful to facilitate access to these types of programs, because the investigators could obtain telematics information about the parameters, reducing cardiovascular risk factors and cardiovascular morbidity and mortality.


Options:
A: Arm Label: Home-based exercise rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Exercise rehabilitation | Arm Label: Supervised exercise rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise rehabilitation | Intervention Type: OTHER; Name: Exercise rehabilitation; Assigned to Arm(s): Home-based exercise rehabilitation, Supervised exercise rehabilitation
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational website.; Type: EXPERIMENTAL; Interventions: Other: Educational website (in addition to usual care). | Arm Label: Website and interactive platform with telemonitoring.; Type: EXPERIMENTAL; Interventions: Other: Website and interactive platform with telemonitoring. | Intervention Type: OTHER; Name: Educational website (in addition to usual care).; Assigned to Arm(s): Educational website. | Intervention Type: OTHER; Name: Website and interactive platform with telemonitoring.; Assigned to Arm(s): Website and interactive platform with telemonitoring.
C: Arm Label: Homebased cardiac rehabilitation program; Type: EXPERIMENTAL; Interventions: Device: Homebased cardiac rehabilitation program, Other: Traditional cardiac rehabilitation program | Arm Label: Traditional cardiac rehabilitation; Type: OTHER; Interventions: Other: Traditional cardiac rehabilitation program | Intervention Type: DEVICE; Name: Homebased cardiac rehabilitation program; Assigned to Arm(s): Homebased cardiac rehabilitation program | Intervention Type: OTHER; Name: Traditional cardiac rehabilitation program; Assigned to Arm(s): Homebased cardiac rehabilitation program, Traditional cardiac rehabilitation
D: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk
Brief Summary: TRACES trial is a multicenter randomized double blind placebo control therapeutic and pharmaco-biological dose ranging study to measure the effect on blood loss reduction of a single intravenous infusion of two doses regimens (standard dose and low dose) of TA administered at the onset of an active PPH (\>800mL) during elective or non-emergent CS and to correlate this clinical effect with the biological effect of fibrinolysis inhibition and the pharmacodynamic measure of TA uterine bleeding and venous blood concentration.


Options:
A: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
D: Arm Label: tranexamic acid 1 g (TA1); Type: EXPERIMENTAL; Interventions: Drug: tranexamic acid 1 g (TA1) | Arm Label: tranexamic acid 0.5 g (TA1/2); Type: EXPERIMENTAL; Interventions: Drug: tranexamic acid 0.5 g (TA1/2) | Arm Label: Saline Solution (TA0); Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline Solution (TA0) | Arm Label: NH; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: tranexamic acid 1 g (TA1); Assigned to Arm(s): tranexamic acid 1 g (TA1) | Intervention Type: DRUG; Name: tranexamic acid 0.5 g (TA1/2); Assigned to Arm(s): tranexamic acid 0.5 g (TA1/2) | Intervention Type: DRUG; Name: Saline Solution (TA0); Assigned to Arm(s): Saline Solution (TA0)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.
Brief Summary: Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over the world. The use of low dose aspirin has been mentioned in several studies with promising results. The investigators decided to evaluate the use of low dose aspirin in Chinese pregnant women, starting between 12+ and 20 weeks of pregnancy, based on clinical characteristics aiming to reduce the incidence of preeclampsia.


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: blank; Type: OTHER; Interventions: Other: Blank | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin | Intervention Type: OTHER; Name: Blank; Assigned to Arm(s): blank
D: Arm Label: Non-intervention group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Low-dose aspirin in women with high risk of preeclampsia | Intervention Type: OTHER; Name: Low-dose aspirin in women with high risk of preeclampsia; Assigned to Arm(s): Intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Cognitus & Moi": a New Cognitive Remediation Tool for Children With Intellectual Deficiency With Behavioral Disorders
Brief Summary: Holders children with intellectual disabilities have great difficulty in adapting to social situations and relationships.Cognitive impairment associated with intellectual disability are important factors to understand their difficulties in processing social information. In the field of recognition of facial emotions in particular, basic cognitive processes such as visuospatial and attentional functions, are heavily involved.Cognitive remediation is a management tool widely used by practitioners to help patients who experience cognitive difficulties. Currently, no program can meet specific and validated the problems are children with intellectual disabilities manner in their daily functioning.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Behavior analytic treatment | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavior analytic treatment; Assigned to Arm(s): Treatment
B: Arm Label: Adult bipolar patients; Type: N/A; Interventions: N/A | Arm Label: Adult Extended Relatives of BD probands; Type: N/A; Interventions: N/A | Arm Label: Bipolar Children and Youth; Type: N/A; Interventions: N/A | Arm Label: Child/Adolescent Extended Relatives of BD probands; Type: N/A; Interventions: N/A | Arm Label: Children with ADHD only (controls); Type: N/A; Interventions: N/A | Arm Label: First degree relatives of BD patients; Type: N/A; Interventions: N/A | Arm Label: Healthy volunteer adults (parents or not); Type: N/A; Interventions: N/A | Arm Label: Healthy volunteer children and youth; Type: N/A; Interventions: N/A
C: Arm Label: Stepping Stones Triple P; Type: EXPERIMENTAL; Interventions: Behavioral: Level 4 Stepping Stones Triple P (SSTP) | Arm Label: Treatment as usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Level 4 Stepping Stones Triple P (SSTP); Assigned to Arm(s): Stepping Stones Triple P
D: Arm Label: Cognitus and Me; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive remediation program | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive remediation program | Intervention Type: BEHAVIORAL; Name: Cognitive remediation program; Assigned to Arm(s): Cognitus and Me, control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The present study is designed to determine whether adjuvant concurrent chemoradiotherapy improves overall survivals.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Concurrent Chemoradiotherapy, Drug: capecitabine, Drug: gemcitabine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: capecitabine, Drug: gemcitabine | Intervention Type: RADIATION; Name: Concurrent Chemoradiotherapy; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Gemcitabine plus Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine
C: Arm Label: Cisplatin plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin and Gemcitabine | Intervention Type: DRUG; Name: Cisplatin and Gemcitabine; Assigned to Arm(s): Cisplatin plus Gemcitabine
D: Arm Label: Test Group; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Apatinib | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Control Group, Test Group | Intervention Type: DRUG; Name: Apatinib; Assigned to Arm(s): Test Group

Answer: A